🔗 Share this article

A shadow market for unlicensed slimming drugs is being driven by social media fitness personalities and vendors on messaging platforms, based on recent findings.

Experimental Drug Gaining Traction Online

The experimental drug, which remains in clinical trials, is being advertised by online personalities for its supposed fat-burning properties. Followers are urged to message these profiles directly for supplier links, while also obtaining discount codes.

Active Commerce on Social Networks

Separately, a flourishing trade exists on Telegram, where communities with numerous of participants share comparison photos, injection guides and assertions of next-day UK delivery. Vendors market the substance there before directing buyers to WhatsApp for transactions.

Learning About Retatrutide

Retatrutide is an investigational injection created by American pharmaceutical company Eli Lilly. The treatment affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials indicate it could help individuals reduce up to 25% of their total weight. Referred to as the “triple G”, the drug is being hailed digitally as the successor to Ozempic.

Medical Experts Express Concerns

However, doctors and pharmacists have warned that the sale of what remains an unapproved drug in the UK is a cause for concern and could result in users administering products of uncertain source.

Several experts stated the demand for retatrutide could be linked to the rising price of approved weight loss products such as Mounjaro.

Regulatory Position and Enforcement

Marketing retatrutide on social media or Telegram is prohibited in the UK, as it is an unapproved medication that must not be promoted or supplied for human use under the Human Medicines Regulations 2012.

Some content creators try to circumvent the regulations by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled substance, but advertising and distribution can still violate medicines, marketing, and consumer regulations, potentially leading to fines, legal action or prison.

Service Reaction and Material Removal

According to the social media company, the service has removed violative content and prohibited associated keywords and search suggestions. The company said it was committed to maintaining the platform safe and allocating resources in strengthening compliance measures.

Online Marketplace Operations

Research also discovered communities with up to 9,000 members marketing the experimental drug using the platform's built-in search feature, which functions like a public directory. Entering “retatrutide” instantly displays groups with numerous of members, populated with photos of slimming results, glowing reviews and detailed guides for preparing or administering at residence.

After moments of entering one community, a seller posted WhatsApp details, where most transactions occur. The seller provided an guidebook and promised shipping within two days. When asked whether the substance was authentic, one seller said: “You can’t be sure.” Another shared a photo of a alleged testing documentation. Not one asked about weight, medical conditions or previous experience.

Product Information and Pricing

Inside these groups, messages display dark colored parcels with postal service labels, stating to include new batches. One message stated: “It took eight of us to load them this morning.”

Buyers can choose between powder vials, mixed at home with sterile water, or ready-to-use pens usually sold at £160 for 20 milligrams. When asked how long a pen should last, vendors give conflicting answers ranging from a several days to “depends on your body”.

Platform Oversight and Security Actions

A representative for the messaging service said it regularly monitored dangerous content on its platform including material that encouraged the “misuse of controlled medications”. The company noted that it eliminated “millions of pieces of harmful content each day”.

Healthcare Expert Cautions

“Individuals are administering materials they cannot confirm. Although the research behind retatrutide is valid, these digital products may not include what they claim,” said a pharmacy expert, the head of pharmacy at a pharmacy service.

A medical professional of an online medical service connected the surge in demand to recent price rises for approved slimming drugs such as Mounjaro. “With prices increasing, individuals are turning to online platforms. But counterfeit treatments are highly risky. You can’t be certain what’s inside or whether the conditions they were produced in was clean,” she said.

Her staff has previously seen patients injured by self-injection from unconfirmed suppliers. “We understand the disappointment, but purchasing from messaging apps or WhatsApp is taking chances with your health,” stated the doctor. “These substances could be impure or improperly measured.”

Manufacturer Position

A spokesperson from Eli Lilly stated retatrutide was in third stage clinical trials and had not been evaluated or authorized by any regulatory agency globally. “Therefore at this time no one can sell [it] for human use,” they said, adding that any item “falsely representing itself as a Lilly experimental substance not yet authorized … may subject users to possibly serious medical dangers”.